ExoGrade
Extracellular Vesicle Therapeutics
Proprietary extracellular vesicle platform
Advancing a lead program toward IND-enabling development, with preclinical proof of concept across inflammation-driven indications.
The Challenge
Dysregulated inflammatory signaling
A major barrier to effective tissue repair across multiple diseases. Modern healthcare often manages downstream consequences rather than modulating the upstream biological drivers of tissue damage.
"Persistent inflammation can impair regenerative capacity and limit durable recovery. There remains a need for mechanism-driven biologics that integrate immune modulation with regenerative signaling."
Our Mission
Building a clinically translatable platform
Our strategy is to advance one lead program toward IND while expanding proof of concept across additional indications. To achieve this, we operate under the following principles:
Biological Rigor
Mechanism-informed design for predictable therapeutic outcomes.
Manufacturing Discipline
Early integration of scalable, reproducible production workflows.
Focused Execution
Translational discipline from discovery through clinical development.
About ExoGrade
Bridging the translational gap in regenerative medicine
ExoGrade is a biotechnology company focused on developing extracellular vesicle therapeutics for inflammation-driven and degenerative conditions.
Why ExoGrade was built differently
We were founded to address a persistent challenge: promising biology often fails due to insufficient integration of manufacturing scalability and regulatory foresight. Our principles include:
Mechanism-informed biological design
Early integration of manufacturing strategy
Translational discipline from discovery onward
Focused capital deployment
Current Stage of Development
- → Lead program advancing toward IND-enabling preparation
- → Multiple preclinical proof-of-concept programs
- → Ongoing platform and process refinement
Platform Overview
Mesenchymal stem cell-derived vesicles
ExoGrade extracellular vesicles are derived from a unique subpopulation of mesenchymal stem cells enriched for pluripotent characteristics. These extracellular vesicles are designed to:
Modulate
Inflammatory signaling pathways
Support
Regenerative tissue responses
Deliver
Reproducible bioactivity
Cell Source Characteristics
- ●Survival in adverse microenvironments
- ●Homing behavior toward injured tissue
- ●Pluripotent differentiation capacity
- ●Self-renewal capabilities
- ●Non-tumorigenic behavior in preclinical evaluation
ExoGrade's Platform Integration
- ●Functional assay development
- ●Scalable upstream expansion
- ●Controlled downstream purification
- ●Early translational development planning
Technical Focus Areas Under Evaluation
These programs reflect the platform's focus on inflammation-mediated tissue damage and regenerative pathway modulation.
Development Portfolio
Robust pipeline
Advancing multiple programs targeting inflammation-driven conditions and regenerative repair.
Leadership
Translational expertise
ExoGrade is led by a team with experience in translational biologics development, extracellular vesicle biology, cell-based manufacturing, and IND-enabling strategy.
Business Development
Decades of leadership experience that spans multiple sectors, including health and wellness.
Platform Development
Extensive experience in preclinical model development and cell/vesicle-based therapeutic platforms.
Scientific and Strategic Advisors
Our accomplished advisors support platform development across biology, manufacturing, and translational strategy to ensure rigorous scientific validation.
Get In Touch
Partner with ExoGrade
We welcome discussions with partners who share our vision for transformative regenerative medicine.
We are looking for